StockData
Niagen Bioscience, Inc. logo

Niagen Bioscience, Inc. (NAGE) stock

NAGENasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3011% below fair value
$2.04+0.03 (+1.49%)

Close on Nov 17, 2026Market cap $161.42MP/E 17.0Yield –

Niagen Bioscience operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Niagen Bioscience's operating cash flow for the twelve months ending Sep 30, 2026 was $4.88M, down 77.2% year over year. For fiscal 2025 it was $13.50M, up 11.5% from the year before. The highest annual figure on record is $13.50M in fiscal 2025.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$13.50M+11.5%
FY2024Dec 31, 2024$12.11M+70.1%
FY2023Dec 31, 2023$7.12M–
FY2022Dec 31, 2022-$15.10M–
FY2021Dec 31, 2021-$24.16M–
FY2020Dec 31, 2020-$10.60M–
FY2019Dec 31, 2019-$20.44M–
FY2018Dec 31, 2018-$20.91M–
FY2017Dec 30, 2017-$9.80M–
FY2016Dec 31, 2016-$2.94M–
FY2015Jan 2, 2016-$2.11M–
FY2014Jan 3, 2015-$2.58M–
FY2013Dec 28, 2013-$3.91M–
FY2012Dec 29, 2012-$10.12M–
FY2011Dec 31, 2011-$4.10M–
FY2010Jan 1, 2011-$2.66M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$2.63M-28.9%
Q2 FY2026Jun 30, 2026$2.77M+121.8%
Q1 FY2026Mar 31, 2026-$1.19M-115.1%
Q4 FY2025Dec 31, 2025$679.00K-92.1%
Q3 FY2025Sep 30, 2025$3.69M+5.6%
Q2 FY2025Jun 30, 2025$1.25M–
Q1 FY2025Mar 31, 2025$7.88M+2572.2%
Q4 FY2024Dec 31, 2024$8.58M+1222.5%
Q3 FY2024Sep 30, 2024$3.50M+782.6%
Q2 FY2024Jun 30, 2024-$264.00K-108.0%
Q1 FY2024Mar 31, 2024$295.00K-89.4%
Q4 FY2023Dec 31, 2023$649.00K–
Q3 FY2023Sep 30, 2023$396.00K–
Q2 FY2023Jun 30, 2023$3.28M–
Q1 FY2023Mar 31, 2023$2.79M–
Q4 FY2022Dec 31, 2022-$328.00K–
Q3 FY2022Sep 30, 2022-$3.74M–
Q2 FY2022Jun 30, 2022-$3.83M–
Q1 FY2022Mar 31, 2022-$7.20M–
Q4 FY2021Dec 31, 2021-$4.94M-22572.7%
Q3 FY2021Sep 30, 2021-$5.92M–
Q2 FY2021Jun 30, 2021-$7.90M–
Q1 FY2021Mar 31, 2021-$5.41M–
Q4 FY2020Dec 31, 2020$22.00K–
Q3 FY2020Sep 30, 2020-$3.85M–
Q2 FY2020Jun 30, 2020-$1.56M–
Q1 FY2020Mar 31, 2020-$5.22M–
Q4 FY2019Dec 31, 2019-$610.00K–
Q3 FY2019Sep 30, 2019-$7.76M–
Q2 FY2019Jun 30, 2019-$9.02M–
Q1 FY2019Mar 31, 2019-$3.05M–
Q4 FY2018Dec 31, 2018-$5.14M–
Q3 FY2018Sep 30, 2018-$5.24M–
Q2 FY2018Jun 30, 2018-$6.55M-3524.9%
Q1 FY2018Mar 31, 2018-$3.99M–
Q4 FY2017Dec 30, 2017-$3.77M–
Q3 FY2017Sep 30, 2017-$475.00K–
Q4 FY2016Dec 31, 2016$191.19K–
Q3 FY2016Oct 1, 2016-$140.40K–

More Niagen Bioscience figures

See a number that looks wrong?